Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Grace K. Dy; Ramaswamy Govindan; Vamsidhar Velcheti; Gerald S. Falchook; Antoîne Italiano; Jürgen Wolf; Adrian G. Sacher; Toshiaki Takahashi; Suresh S. Ramalingam; Christophe Dooms; Dong‐Wan Kim; Alfredo Addeo; Jayesh Desai; Martin Schüler; Pascale Tomasini; David S. Hong; Piro Lito; Qui Tran; Simon Jones; Abraham Anderson; Antreas Hindoyan; Wendy Snyder; Ferdinandos Skoulidis; Bob T. Li

doi:10.1200/jco.22.02524

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

alterations, and was associated with lower baseline circulating tumor DNA levels. Sotorasib was well tolerated, with few late-onset treatment-related toxicities, none of which led to treatment discontinuation. These results demonstrate the long-term benefit of sotorasib, including in subgroups with poor prognosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dy et al. (2023) studied this question.

synapsesocial.com/papers/69faa20d8dfb8b4becd2e757 https://doi.org/10.1200/jco.22.02524

View Full Paper

Ask AI

Bookmark

Share

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Ask about this paper

Abstract

Discussion

Cite This Study

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading